Teva Pharmaceutical Industries Limited logo TEVA - Teva Pharmaceutical Industries Limited

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 22
HOLD 20
SELL 4
STRONG
SELL
0
| PRICE TARGET: $41.00 DETAILS
HIGH: $42.00
LOW: $40.00
MEDIAN: $41.00
CONSENSUS: $41.00
UPSIDE: 27.41%

About Teva Pharmaceutical Industries Limited (https://www.tevapharm.com)

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Key Executives

NAME TITLE DOB SALARY
Richard Francis President, Chief Executive Officer & Director 1968 $7,168,739 USD
Eliyahu Sharon Kalif Executive Vice President & Chief Financial Officer 1974 $3,162,002 USD
Eric A. Hughes Executive Vice President of Global R&D and Chief Medical Officer 1970 $2,548,950 USD
Christine Fox Executive VP of US Commercial & Head of Innovative Franchise 1969 $2,495,184 USD
Evan Lippman Executive Vice President of Business Development 1970 $2,322,034 USD
Matthew Shields Executive Vice President of Global Operations 1975 $2,254,090 USD
Amir Weiss Senior Vice President & Chief Accounting Officer 1977
Brian Savage Interim Chief Legal Officer
Christopher J. Stevo Senior Vice President of Investor Relations & Competitive Intelligence
Kathleen Veit Senior Vice President, Global Compliance & Ethics Officer

Company Peers

Peer analysis pending, check back in 1-2 minutes.